The upcoming Phase 2 data readout is a high-impact binary event. Traders should monitor the May 27 results and conference call for efficacy and safety signals. Positive data could drive substantial upside given the large I&I market opportunity; negative data could lead to significant downside.
Price Chart
Executive Summary
Apogee Therapeutics announced it will release Part B 16-week data from the Phase 2 APEX trial of zumilokibart on May 27, 2026, followed by a conference call. This is a binary catalyst event for the clinical-stage biotech, as zumilokibart is its most advanced program targeting atopic dermatitis, asthma, and eosinophilic esophagitis.
Key Facts
- Part B 16-week data from Phase 2 APEX trial of zumilokibart to be reported on May 27, 2026.
- Conference call and webcast scheduled for 8:00 a.m. ET on May 27, 2026.
- Zumilokibart is Apogee's most advanced program, targeting atopic dermatitis, asthma, and EoE.
- Apogee is a clinical-stage biotechnology company with no approved products or reported revenue.
Financial Impact
No financial data provided; outcome of data readout could significantly impact valuation given early-stage nature.
Risk Factors
- Negative or mixed Phase 2 data could severely impact stock price, as zumilokibart is the lead asset.
- Clinical-stage biotech with no revenue; cash runway and future financing needs depend on trial outcomes.
- Historical performance shows past high-score calls on APGE have had negative average returns, suggesting market skepticism.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301436 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 15-12G | — | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 25-NSE | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 8-K | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Aug 11, 2026 7w ago | 8-K | $134.55 $134.71 | ▲ +0.12% | ▲ +0.56% | — |
Aug 10, 2026 7w ago | 8-K | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 10, 2026 7w ago | Press Release | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 6, 2026 8w ago | Institutional Cluster | $134.49 $134.45 | ▼ −0.03% | ▼ −1.24% | — |
Aug 3, 2026 8w ago | DEFA14A | $134.19 $134.69 | ▲ +0.37% | ▲ +0.47% | — |
Jul 11, 2026 11w ago | Insider Cluster | $133.82 $134.00 | ▲ +0.13% | ▲ +0.92% | — |
Jun 26, 2026 13w ago | DEFA14A | $132.61 $133.50 | ▲ +0.67% | ▼ −0.72% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access